Haemonetics Shares Rise Over 17% on Plasma Supply Agreement with CSL
Haemonetics (HAE) shares surged more than 17% following the announcement of a non-exclusive plasma supply agreement with CSL. The stock reached $119.47, setting a new 52-week high and marking significant investor interest in this development. The deal is expected to enhance Haemonetics' revenue streams by securing access to critical raw materials for its medical technology products. This partnership could strengthen the company's market position within the healthcare sector as it expands supply chain capabilities with one of the industry leaders, CSL. Investors responded positively, pushing HAE stock higher and signaling optimism about future growth potential tied to this strategic collaboration.
Tickers: $HAE
Topics: medical technology plasma supply agreement stock rally